ECSP13013047A - Nuevos derivados de imidazol útiles para el tratamiento de artritis - Google Patents
Nuevos derivados de imidazol útiles para el tratamiento de artritisInfo
- Publication number
- ECSP13013047A ECSP13013047A ECSP13013047A ECSP13013047A EC SP13013047 A ECSP13013047 A EC SP13013047A EC SP13013047 A ECSP13013047 A EC SP13013047A EC SP13013047 A ECSP13013047 A EC SP13013047A
- Authority
- EC
- Ecuador
- Prior art keywords
- arthritis
- treatment
- derivatives useful
- imidazol derivatives
- new
- Prior art date
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 206010003246 arthritis Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a compuestos de la fórmula siguiente:donde A, X y R1-R6 son como se describen en la presente, una sal farmacéutica del mismo, y una composición farmacéutica que contiene este compuesto; métodos para tratar dolor asociado con osteoartritis usando uno de los compuestos o una sal
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490222P | 2011-05-26 | 2011-05-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP13013047A true ECSP13013047A (es) | 2014-01-31 |
Family
ID=46148987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSP13013047 ECSP13013047A (es) | 2011-05-26 | 2013-11-25 | Nuevos derivados de imidazol útiles para el tratamiento de artritis |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8648200B2 (es) |
| EP (1) | EP2714679A1 (es) |
| JP (1) | JP2014518886A (es) |
| KR (1) | KR20130143138A (es) |
| CN (1) | CN103562200A (es) |
| AR (1) | AR086254A1 (es) |
| AU (1) | AU2012259234A1 (es) |
| BR (1) | BR112013029692A2 (es) |
| CA (1) | CA2836240A1 (es) |
| CO (1) | CO6811858A2 (es) |
| CR (1) | CR20130534A (es) |
| DO (1) | DOP2013000276A (es) |
| EA (1) | EA201391568A1 (es) |
| EC (1) | ECSP13013047A (es) |
| IL (1) | IL229318A0 (es) |
| MA (1) | MA35128B1 (es) |
| MX (1) | MX2013013859A (es) |
| PH (1) | PH12013502435A1 (es) |
| SG (1) | SG195020A1 (es) |
| TN (1) | TN2013000434A1 (es) |
| TW (1) | TW201311658A (es) |
| WO (1) | WO2012161965A1 (es) |
| ZA (1) | ZA201308609B (es) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8871947B2 (en) | 2013-02-04 | 2014-10-28 | KingChem LLC | Preparation of alkyl 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid ester |
| CN103467379A (zh) * | 2013-08-23 | 2013-12-25 | 江苏恒安化工有限公司 | 3-三氟甲基-1-甲基吡唑-4-甲酸的制备方法 |
| CN103601675B (zh) * | 2013-10-08 | 2015-10-28 | 南京复兴生物科技有限公司 | 一种5-氨甲基烟酸的制备方法 |
| CN103483250B (zh) * | 2013-10-08 | 2015-07-22 | 南京复兴生物科技有限公司 | 一种5-氨甲基烟酸的制备方法 |
| WO2015085464A1 (en) | 2013-12-09 | 2015-06-18 | King Chem, Llc | Process for preparing alkyl 3-difluoromethyl-1-methyl-1h-pyrazole-4-carboxylate and its analogs |
| TWI651310B (zh) | 2014-02-20 | 2019-02-21 | 日商日本煙草產業股份有限公司 | 三化合物及其醫藥用途 |
| JP6566444B2 (ja) | 2014-03-19 | 2019-08-28 | カーザ グローバル エルエルシーCurza Global, Llc | 2−(アシルアミノ)イミダゾールを含む組成物および方法 |
| KR20160134865A (ko) | 2014-04-14 | 2016-11-23 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | 아미드 유도체 및 이의 약제학적으로 허용되는 염, 이의 제조방법 및 이의 의학적 적용 |
| US20170057943A1 (en) | 2015-08-17 | 2017-03-02 | Japan Tobacco Inc. | Hydroxytriazine compounds and pharmaceutical use thereof |
| JP2020512981A (ja) | 2017-03-31 | 2020-04-30 | カーザ グローバル,リミティド ライアビリティ カンパニー | 置換2−アミノイミダゾールを含む組成物と方法 |
| CN109293567A (zh) * | 2018-11-23 | 2019-02-01 | 上海睿腾医药科技有限公司 | 一种5-溴-2-甲基烟酸乙酯的合成方法 |
| BR112021025132A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Carbamatos de piridina e seu uso como moduladores do receptor glun2b |
| CN114245807B (zh) | 2019-06-25 | 2025-05-02 | 吉利德科学公司 | Flt3l-fc融合蛋白和使用方法 |
| PH12022550835A1 (en) | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
| NZ786589A (en) | 2019-10-31 | 2025-03-28 | Forty Seven Llc | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| CN110845426A (zh) * | 2019-11-29 | 2020-02-28 | 都创(上海)医药科技有限公司 | 一种2-氯-5-氰基嘧啶化合物制备方法 |
| CN115362003B (zh) | 2019-12-24 | 2024-03-22 | 卡尔那生物科学株式会社 | 二酰基甘油激酶调节化合物 |
| US12599589B2 (en) | 2019-12-25 | 2026-04-14 | Nippon Shinyaku Co., Ltd. | Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome |
| TWI890283B (zh) | 2020-02-14 | 2025-07-11 | 美商基利科學股份有限公司 | 結合ccr8之抗體及融合蛋白及其用途 |
| JP7564888B2 (ja) | 2020-05-01 | 2024-10-09 | ギリアード サイエンシーズ, インコーポレイテッド | Cd73阻害性2,4-ジオキソピリミジン化合物 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
| WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| JP7651018B2 (ja) | 2021-06-23 | 2025-03-25 | ギリアード サイエンシーズ, インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| MX2023014762A (es) | 2021-06-23 | 2024-01-15 | Gilead Sciences Inc | Compuestos moduladores de diacilglicerol quinasa. |
| CN117355531A (zh) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4423078A1 (en) | 2021-10-28 | 2024-09-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| PE20241186A1 (es) | 2021-10-29 | 2024-06-03 | Gilead Sciences Inc | Compuestos de cd73 |
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| US20240124412A1 (en) | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| CN118748993A (zh) | 2021-12-28 | 2024-10-08 | 日本新药株式会社 | 吲唑化合物和药物 |
| CA3248911A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | POLY(ADENOSINE DIPHOSPHATE-RIBOSE) POLYMERASE 7 INHIBITORS |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| AU2023240346A1 (en) | 2022-03-24 | 2024-09-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| EP4511127A1 (en) | 2022-04-21 | 2025-02-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| EP4638436A1 (en) | 2022-12-22 | 2025-10-29 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| PE20260121A1 (es) | 2023-04-21 | 2026-01-16 | Gilead Sciences Inc | Inhibidores de prmt5 y usos de los mismos |
| JP2026522894A (ja) | 2023-06-30 | 2026-07-09 | ギリアード サイエンシーズ, インコーポレイテッド | Kras調節化合物 |
| CN121568935A (zh) | 2023-07-26 | 2026-02-24 | 吉利德科学公司 | Parp7抑制剂 |
| AU2024297978A1 (en) | 2023-07-26 | 2026-02-05 | Gilead Sciences, Inc. | Parp7 inhibitors |
| EP4774280A1 (en) | 2023-09-08 | 2026-07-15 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20250109147A1 (en) | 2023-09-08 | 2025-04-03 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| CN119161260A (zh) * | 2024-06-26 | 2024-12-20 | 安徽大学 | 一种1-(2-氨基-4-氟-5-甲氧基苯基)-1-丙酮的合成方法 |
| US20260098049A1 (en) | 2024-08-12 | 2026-04-09 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20260130893A1 (en) | 2024-10-21 | 2026-05-14 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2026136515A1 (en) | 2024-12-19 | 2026-06-25 | Gilead Sciences, Inc. | Parp7 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005295752A1 (en) * | 2004-10-15 | 2006-04-27 | Amgen Inc. | Imidazole derivatives as vanilloid receptor ligands |
| US8084466B2 (en) * | 2007-12-18 | 2011-12-27 | Janssen Pharmaceutica Nv | Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine H4 receptor |
| WO2009103778A1 (en) | 2008-02-19 | 2009-08-27 | Novasaid Ab | Compounds and methods |
| UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
| WO2010127152A2 (en) * | 2009-04-29 | 2010-11-04 | Irm Llc | Compounds and compositions as microsomal prostaglandin e synthase-1 inhibitors |
| JP5579862B2 (ja) | 2009-10-23 | 2014-08-27 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ミクロソームプロスタグランジンe2シンターゼ−1のインヒビター |
| AR084174A1 (es) * | 2010-12-21 | 2013-04-24 | Lilly Co Eli | Compuestos de imidazol-2-benzamida utiles para el tratamiento de osteoartritis y una composicion farmaceutica |
-
2012
- 2012-05-03 AR ARP120101556A patent/AR086254A1/es not_active Application Discontinuation
- 2012-05-04 TW TW101116086A patent/TW201311658A/zh unknown
- 2012-05-10 BR BR112013029692A patent/BR112013029692A2/pt not_active IP Right Cessation
- 2012-05-10 CA CA2836240A patent/CA2836240A1/en not_active Abandoned
- 2012-05-10 AU AU2012259234A patent/AU2012259234A1/en not_active Abandoned
- 2012-05-10 US US13/468,122 patent/US8648200B2/en not_active Expired - Fee Related
- 2012-05-10 KR KR1020137030893A patent/KR20130143138A/ko not_active Ceased
- 2012-05-10 CN CN201280025230.2A patent/CN103562200A/zh active Pending
- 2012-05-10 SG SG2013085154A patent/SG195020A1/en unknown
- 2012-05-10 EP EP12723323.7A patent/EP2714679A1/en not_active Withdrawn
- 2012-05-10 EA EA201391568A patent/EA201391568A1/ru unknown
- 2012-05-10 MX MX2013013859A patent/MX2013013859A/es unknown
- 2012-05-10 WO PCT/US2012/037200 patent/WO2012161965A1/en not_active Ceased
- 2012-05-10 PH PH1/2013/502435A patent/PH12013502435A1/en unknown
- 2012-05-10 JP JP2014512861A patent/JP2014518886A/ja active Pending
-
2013
- 2013-10-18 CR CR20130534A patent/CR20130534A/es unknown
- 2013-10-24 TN TNP2013000434A patent/TN2013000434A1/fr unknown
- 2013-11-07 IL IL229318A patent/IL229318A0/en unknown
- 2013-11-15 MA MA36452A patent/MA35128B1/fr unknown
- 2013-11-15 ZA ZA2013/08609A patent/ZA201308609B/en unknown
- 2013-11-22 CO CO13275568A patent/CO6811858A2/es not_active Application Discontinuation
- 2013-11-22 DO DO2013000276A patent/DOP2013000276A/es unknown
- 2013-11-25 EC ECSP13013047 patent/ECSP13013047A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG195020A1 (en) | 2013-12-30 |
| CA2836240A1 (en) | 2012-11-29 |
| IL229318A0 (en) | 2014-01-30 |
| MA35128B1 (fr) | 2014-05-02 |
| CR20130534A (es) | 2014-03-12 |
| EP2714679A1 (en) | 2014-04-09 |
| AR086254A1 (es) | 2013-11-27 |
| TW201311658A (zh) | 2013-03-16 |
| JP2014518886A (ja) | 2014-08-07 |
| EA201391568A1 (ru) | 2014-04-30 |
| KR20130143138A (ko) | 2013-12-30 |
| TN2013000434A1 (en) | 2015-03-30 |
| CN103562200A (zh) | 2014-02-05 |
| MX2013013859A (es) | 2014-05-28 |
| ZA201308609B (en) | 2015-05-27 |
| AU2012259234A1 (en) | 2013-11-14 |
| DOP2013000276A (es) | 2014-03-31 |
| WO2012161965A1 (en) | 2012-11-29 |
| PH12013502435A1 (en) | 2014-01-13 |
| US20120302608A1 (en) | 2012-11-29 |
| CO6811858A2 (es) | 2013-12-16 |
| US8648200B2 (en) | 2014-02-11 |
| BR112013029692A2 (pt) | 2017-01-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2013000276A (es) | Nuevos derivados de imidazol útiles para el tratamiento de artritis | |
| ECSP18094790A (es) | Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas | |
| CR20140301A (es) | Derivados de betulina | |
| CY1121549T1 (el) | Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων | |
| DOP2017000278A (es) | Piridinas sustituidas y método de uso | |
| CO6710897A2 (es) | Derivados de poperdinona como inhibidores mdm2 para el tratamiento del cáncer | |
| UY35243A (es) | Inhibidores de fosfatidilinositol 3-cinasa | |
| MX381235B (es) | Análogos de éter fosfolipídico como portadores de fármacos dirigidos a cáncer. | |
| MX2015012427A (es) | Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer. | |
| UY32096A (es) | Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones | |
| ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| UY35353A (es) | Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer | |
| EA201690247A1 (ru) | Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения | |
| CO6801794A2 (es) | Derivados de isoxazolina en el tratamiento de ectoparasitos y su proceso de producción | |
| BR112012019762A2 (pt) | composto, composição, e, método para tratar uma doença. | |
| SV2011003997A (es) | Pirimidinas fusionadas | |
| UY35143A (es) | Derivados de dihidropirazol como moduladores del receptor acoplado a la proteína gpr40 g | |
| DOP2014000178A (es) | Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2 | |
| UY35325A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| DOP2014000177A (es) | Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2 | |
| EA201600323A1 (ru) | Производные пиперазина и их применение в качестве лекарственного средства | |
| EA201590656A1 (ru) | Азаиндолины | |
| MX2014000344A (es) | Antagonistas de trpv1 que incluyen sustituyente dihidroxi y sus usos. | |
| UY35766A (es) | Proceso industrial para la síntesis de ingredientes activos esteroides |